Peptides: What They Are & Why People Inject Them ...

Quick Answer: Peptides are short chains of amino acids, and the word covers two completely different things. FDA-approved peptide medications — semaglutide (Wegovy) and tirzepatide (Zepbound) — have robust trial evidence for 15 to 20 percent weight loss. Research peptides sold online, such as BPC-157, TB-500 and AOD-9604, are unapproved drugs with no completed human safety trials. That second category shifted in 2026: the FDA removed several from its Category 2 safety-risk list in April, and in July an advisory committee narrowly recommended six for compounding eligibility — overruling the agency's own scientists. None of them is legal to compound today, and all remain banned in sport.

Table of Contents

• The Peptide Craze, Explained
• What Peptides Actually Are
• Why People Inject Them
• Two Very Different Categories
• FDA-Approved Peptide Medications
• Unapproved "Research" Peptides
• What the Evidence Says
• Where the Law Stands in 2026
• Common Mistakes
• Better Ways to Reach Your Goals
• Frequently Asked Questions
• The Bottom Line
• References

The Peptide Craze, Explained

There is a peculiar inversion running through this topic. People will happily inject a compound bought from an overseas website with no quality control, while treating medications that went through years of controlled trials as suspicious pharmaceutical overreach.

Both are peptides. They are not remotely comparable.

On one side sit semaglutide and tirzepatide — approved, studied in tens of thousands of participants, with known risks and known benefits. On the other sit BPC-157, TB-500 and a long tail of compounds promoted through TikTok and Reddit on the strength of rodent studies.

The regulatory picture around that second group moved substantially in 2026, in a direction most articles on this subject have not caught up with. This guide covers what peptides are, which have evidence behind them, where the law actually stands as of August 2026, and what to do instead if your goal is weight loss or recovery.

New to GLP-1s? You're not alone.

Get our free GLP-1 nutrition guide — what to eat, what to expect, and how to get the best results.

What Peptides Actually Are

Peptides are short chains of amino acids — mini-proteins, in effect. Proteins run to hundreds or thousands of amino acids; peptides typically have between 2 and 50.

Your body makes thousands of them, and several are among its most important signalling molecules. Insulin is a peptide. So is GLP-1, the hormone that regulates blood sugar and appetite and gives the weight loss drugs their name. So is growth hormone.

They work by binding to specific receptors on cell surfaces, each peptide fitting a particular lock and triggering a particular response. GLP-1 receptor agonists mimic the natural hormone: slower gastric emptying, reduced appetite, better glucose regulation. Well-understood biochemistry rather than anything exotic.

The peptides people inject are synthetic, whether approved or not. What separates them is oversight. Approved drugs are made under enforced quality controls and tested in trials. Research peptides bought online are made without any of that, and independent testing has repeatedly found products that are impure, contaminated, or not what the label says.

Why People Inject Them

Weight loss is far and away the biggest driver, and the one category where the evidence is genuinely strong — for the approved medications.

Injury recovery is next: BPC-157 and TB-500 are promoted for tendon and muscle healing on the basis of animal work, with essentially no human trial data.

Muscle and performance claims attach to growth hormone secretagogues like CJC-1295 and ipamorelin. Weak evidence, and banned in competitive sport.

Beyond those, various peptides are sold for anti-aging and cosmetic purposes with minimal backing, and for sexual health — where bremelanotide (Vyleesi) is genuinely approved for a narrow indication while unapproved lookalikes circulate online.

Two Very Different Categories

Category	Examples	FDA status	Evidence	Safety profile
Approved medications	Semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro)	Fully approved	Large randomized trials, thousands of participants	Documented; risks known and monitorable
Unapproved "research" peptides	BPC-157, TB-500, AOD-9604, CJC-1295, ipamorelin, melanotan	Not approved for any human use	Largely animal studies; little human data	Unknown; purity and contamination concerns

Collapsing these two into one word is how people end up making bad decisions, and it suits the people selling the second category perfectly.

FDA-Approved Peptide Medications

GLP-1 and GIP receptor agonists

In the STEP-1 trial, participants on semaglutide 2.4mg weekly lost an average of 14.9% of body weight over 68 weeks against 2.4% on placebo. SURMOUNT-1 found tirzepatide reached up to 22.5% at the highest dose over 72 weeks. And a 2025 head-to-head trial put tirzepatide at 20.2% against semaglutide at 13.7%.

Outside bariatric surgery, nothing else in obesity medicine comes close to those numbers. Every one of those trials also ran alongside structured lifestyle intervention, which is the part that gets left out of the marketing.

Our Ultimate Guide to the GLP-1 Diet covers the nutrition side properly, and if you are just starting, the first week guide is the more immediately useful read.

Other approved peptide drugs

Tesamorelin is approved for HIV-associated lipodystrophy — a specific condition, not a general weight loss drug, whatever some clinics imply. Bremelanotide (Vyleesi) is approved for hypoactive sexual desire disorder in premenopausal women. Narrow indications, narrow populations.

Unapproved "Research" Peptides

BPC-157

The most hyped of the group. A synthetic 15-amino-acid peptide derived from a protein in gastric juice, promoted for healing more or less everything.

The research is almost entirely animal work. A systematic review of its use in orthopaedic sports medicine found no quality human clinical trials, and when FDA career scientists reviewed it in 2026 alongside six other peptides, they concluded it did not meet the agency's evidentiary standard. There is no completed human trial of injectable BPC-157.

TB-500

A synthetic fragment of thymosin beta-4, a protein involved in wound healing. Same shape of story: animal studies suggesting promise, essentially no human safety or efficacy data.

Growth hormone secretagogues

CJC-1295, ipamorelin and GHRP-6 are marketed to stimulate natural growth hormone production. Popular in bodybuilding and anti-aging circles, minimal human data, no approval, and significant quality control concerns in the supply chain.

Melanotan I and II

Sold to produce tanning without sun exposure, with side effects on appetite and sexual function. Completely unregulated, with documented risks including nausea, flushing, and effects on blood pressure and heart rate. Regulators including Australia's TGA have issued explicit consumer warnings. The unknowns around moles and skin cancer risk make this the least defensible category on the page.

What the Evidence Says

Weight loss, for approved medications: strong. Multiple large randomized trials, consistent effects, sustained over a year or more.

One caveat worth stating precisely, because it is widely garbled. A meaningful share of the weight lost on these medications is lean mass rather than fat — published trial data puts it somewhere between roughly a quarter and 40 percent depending on the drug and the study. Research presented to the Endocrine Society in 2025 found that among people on semaglutide, lower protein intake was associated with greater muscle loss. That is an association, not proof that protein prevents it, and you will see the figure quoted as a certainty far more often than the data supports. Our guide to preventing muscle loss on GLP-1 medications goes through it properly.

Muscle and performance: weak. Minimal quality human data for any of the secretagogues, against an enormous evidence base for progressive resistance training and adequate protein.

Healing and recovery: very weak. Animal results frequently fail to translate, and drug development is littered with compounds that looked excellent in rodents and harmed humans. That gap matters more, not less, when the compound is being injected.

Tanning and cosmetic: actively discouraged by regulators in multiple countries.

Where the Law Stands in 2026

Important distinction: "unapproved" and "off-label" are not the same thing. Off-label use means an FDA-approved drug prescribed for a condition other than its approved indication. Most peptides sold online are unapproved new drugs — never approved for any human use at all. Nearly everyone gets this wrong.

What changed in 2026

This section is where most articles on peptides are now out of date, including the earlier version of this one.

Until recently, BPC-157 and TB-500 sat on the FDA's Category 2 list of bulk drug substances that "may present significant safety risks," where they had been placed in 2023. In April 2026 the FDA removed them — along with CJC-1295 and several others — from Category 2, following withdrawal of their nominations. Crucially, the agency did not move them to Category 1, the list of substances permitted for compounding. They landed in a gray zone: neither formally flagged as risky nor authorized.

Then on 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee met to consider seven peptides for the 503A Bulks List. It recommended six: BPC-157, KPV and TB-500 each passed 8-6, MOTS-c 7-5, Semax 8-5 and Epitalon 7-5. Only emideltide (DSIP) was rejected.

Two things about those votes deserve emphasis, because the headline alone is misleading.

First, the committee voted against the written recommendation of FDA career staff in every single case. Agency scientists had reviewed all seven and concluded that none met the four-part evidentiary standard for inclusion. The panel overruled them six consecutive times, by margins of one or two votes.

Second, and more practically: a PCAC recommendation is advisory and non-binding. The FDA must still run notice-and-comment rulemaking, which typically takes the better part of a year. None of these six is legal to compound as of August 2026, and none is FDA-approved for any human indication. Anything sold to you today as legal on the strength of that vote is being misrepresented.

Separately, in April 2026 the FDA proposed removing GLP-1 receptor agonists from the 503B outsourcing facility list as the shortage resolved — which narrows the legitimate compounded semaglutide and tirzepatide market further still.

Sport and military rules have not moved

Nothing above changes anti-doping status. WADA prohibits BPC-157 at all times under the S0 non-approved substances category, and TB-500 has been banned since 2011. USADA has been blunt about it, and the Department of Defense warns service members against BPC-157 through its Operation Supplement Safety programme. A compounding recommendation is not a doping exemption.

Enforcement

The FDA has issued numerous warning letters to peptide vendors, and the Department of Justice has prosecuted pharmacies for distributing unapproved peptides. Enforcement has historically targeted sellers rather than individual buyers, which is why this market operates openly — but "rarely prosecuted" and "legal" are different things, and the distinction matters if you are a prescriber, an athlete, or in the military.

Common Mistakes

Assuming "your body makes it" means safe to inject. Dose, purity, route and timing all change the picture entirely.

Trusting underground suppliers. Testing has found impurities, contamination, and products containing something other than what the label claims. You do not know what is in the vial.

Reading the July 2026 vote as legalisation. It was an advisory recommendation against the agency's own scientific staff, and rulemaking has not happened. Expect this to be misrepresented heavily by sellers over the next year.

Beyond those, the recurring ones: treating "I bought it online" as evidence of legality; expecting any peptide to substitute for nutrition and training; reading rodent studies as human evidence; going around a doctor even with approved medications, which have real contraindications and interactions; and neglecting protein while on a GLP-1, which is the single most consequential nutrition mistake in this whole area.

Better Ways to Reach Your Goals

Built for Your GLP-1 Plan

Our GLP-1 Meal Plan is designed for people on Ozempic, Wegovy, Mounjaro and Zepbound — high protein, portion-controlled, and gentle on a slowed stomach. No subscription required.

View GLP-1 Meal Plan →

For weight loss

If you are a candidate for medication, that conversation belongs with your doctor and involves an approved drug, not an online vendor.

The fundamentals hold either way. A sustainable deficit of 300 to 500 calories below maintenance. Protein at 1.2 to 1.6 grams per kilogram of body weight daily during active weight loss on a GLP-1, which is roughly 20 to 40 grams per meal for most people. Resistance training two to three times a week to protect lean mass. And seven to nine hours of sleep — our guide to sleep and health covers why that is not optional.

For the food side, our 100 Best Foods for Weight Loss guide is the deeper resource, and the Weight Loss Meal Plan handles portion control if that is the part that keeps slipping.

For muscle and recovery

Skip the underground peptides entirely. What works is unglamorous and well established: progressive strength training, 1.4 to 2.0 grams of protein per kilogram daily spread across four or more feedings, a slight calorie surplus if you are building, proper sleep, and creatine monohydrate at 3 to 5 grams daily — one of the very few supplements with a genuinely robust evidence base.

Our High Protein Meal Plan delivers 35g+ per meal, and our supplements guide applies the same evidentiary standard to everything else on the shelf.

For general fitness

Our complete exercise guide covers what actually moves the needle. It is not a shortcut, which is precisely the point.

Frequently Asked Questions

Are peptide injections safe?

It depends entirely on which peptide. FDA-approved medications such as semaglutide and tirzepatide have known risk profiles and are safe when prescribed and monitored. Research peptides sold online, including BPC-157 and TB-500, have never completed human safety trials. In July 2026 FDA career scientists reviewing seven of these compounds concluded that none met the agency's evidentiary standard for safety and effectiveness.

Is BPC-157 legal in 2026?

Not for human use, though the picture has moved. In April 2026 the FDA removed BPC-157 from its Category 2 list of substances posing significant safety risks, after the nominations were withdrawn, but did not move it to Category 1. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding it to the 503A Bulks List. That vote is advisory only. The FDA must still complete notice-and-comment rulemaking, so BPC-157 remains illegal to compound today and is not FDA-approved for any human indication.

How much weight can you lose on GLP-1 medications?

In the STEP-1 trial, semaglutide 2.4mg produced average weight loss of 14.9% against 2.4% for placebo over 68 weeks. SURMOUNT-1 found tirzepatide reached up to 22.5% at the highest dose over 72 weeks. A 2025 head-to-head trial put tirzepatide at 20.2% against semaglutide's 13.7%. Individual results vary considerably, and all of these trials ran alongside lifestyle intervention.

What are the side effects of GLP-1 medications?

Nausea, vomiting, diarrhoea, constipation and stomach pain are common, particularly while the dose is being escalated, and usually ease over time. Less common concerns include gallbladder problems and rare pancreatitis signals. Semaglutide carries a boxed warning about thyroid C-cell tumours based on rodent studies. Discuss your own risk profile with your prescriber.

Can I get compounded semaglutide or tirzepatide?

Compounding discretion has narrowed sharply since the shortages resolved, and in April 2026 the FDA proposed removing GLP-1 receptor agonists from the 503B outsourcing facility list entirely. The agency has issued warning letters to vendors selling unapproved GLP-1 products. Work with a licensed prescriber and a legitimate pharmacy rather than an online seller.

What is the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 receptor agonist, acting on one receptor. Tirzepatide is a dual GIP and GLP-1 receptor agonist, acting on two. In a 2025 head-to-head trial over 72 weeks, tirzepatide produced greater average weight loss and waist reduction, 20.2% against 13.7%. Side effect profiles are broadly similar.

Do peptides show up on drug tests?

Standard employment and legal drug screens do not test for peptides. Anti-doping testing is a different matter: WADA prohibits BPC-157 at all times under the S0 non-approved substances category, and TB-500 has been banned since 2011. The July 2026 compounding recommendations change nothing here. If you are subject to testing, these remain prohibited.

What should I eat while on GLP-1 medication?

Protein first, at every meal. A 2025 joint advisory from several professional societies recommends 1.2 to 1.6 grams of protein per kilogram of body weight daily during active weight loss on these medications, roughly 20 to 40 grams per meal for most people. Add fibre for fullness and digestive comfort, keep meals smaller and more frequent while appetite is suppressed, and pair the medication with resistance training to protect lean mass.

The Bottom Line

The confusion in this category is not accidental. Blurring the line between approved medications and research chemicals is commercially useful to the people selling the latter.

The approved peptide drugs are a genuine advance in obesity treatment, with evidence, known risks and medical oversight. If you are a candidate, that is a conversation worth having with a doctor.

The unapproved ones have no completed human trials, uncertain purity, and a regulatory status that in August 2026 is best described as unresolved. An advisory panel narrowly recommended six of them for compounding eligibility over the objections of the agency's own reviewers, and the rulemaking that would actually change anything has not happened. Nothing about that vote makes them safe, tested, or currently legal — and it changes nothing at all if you are drug tested.

Whatever the goal, the boring parts still do most of the work: enough protein, consistent training, adequate sleep, a sensible calorie target. Peptides, even the good ones, are tools that sit on top of that foundation rather than replacing it.

If the nutrition side is where you keep slipping, our meal plans are built by dietitians for exactly these goals — protein-forward and portion-controlled, whether you are on a GLP-1 or building muscle without one.

This article is for educational purposes only and does not constitute medical or legal advice. Regulatory status in this area is changing rapidly; verify current FDA guidance and consult a licensed healthcare provider before starting or stopping any medication or supplement. Regulatory position verified August 2026.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. NEJM
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. NEJM
3. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025;393:26-36. NEJM
4. FDA. Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026. FDA.gov
5. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA.gov
6. USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. USADA.org
7. Operation Supplement Safety. BPC-157: A prohibited peptide and an unapproved drug. OPSS.org
8. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. PMC
9. TGA. Consumer warning about melanotan products. TGA.gov.au